SEARCH

SEARCH BY CITATION

References

  • Blanco, F.J., Ochs, R.L., Schwarz, H. and Lotz, M. (1995) Chondrocyte apoptosis induced by nitric oxide. Am. J. Pathol. 146, 7585.
  • Conrozier, T. (1998) Death of articular chondrocytes. Mechanisms and protection. Presse Med. 27, 18591861.
  • Das, A.J. and Hammad, T.A. (2000) Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulphate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cart. 8, 343350.
  • Fenton, J.L., Chlebek-Brown, K.A., Peters, T.L., Caron, J.P. and Orth, M.W. (2000) Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cart. 8, 258265.
  • Gouze, J.N., Bordji, K., Gulberti, S., Terlain, B., Netter, P., Magdalou, J., Fournel-Gigleux, S. and Ouzzine, M. (2001) Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: influence of glucosamine on interleukin-1 beta-mediated effects in rat chondrocytes. Arthr. Rheum. 44, 351360.
  • Grabowski, P.S., England, A.J., Dykhuizen, R., Copland, M., Benjamin, N., Reid, D. M. and Ralston, S.H. (1996) Elevated nitric oxide production in rheumatoid arthritis. Arthr. Rheum. 39, 643647.
  • Hanson, R.R., Smalley, L.R., Huff, H.F., White, S. and Hammad, T.A. (1997) Oral treatment with a glucosamine-chondroitin sulphate compound for degenerative joint disease in horses: 25 cases. Equine Pract. 9, 1622.
  • Hanson, R.R., Brawner, W.R., Blaik, M.A., Hammad, T.A., Kincaid, S.A. and Pugh, D.G. (2001) Oral treatment with a Nutraceutical (Cosequin) for ameliorating signs of navicular syndrome in horses. Vet. Therap. 2, 148159.
  • Kirkerhead, C. and Kirkerhead, R. (2001) Safety of an oral chondroprotective agent in horses. Vet. Therap. 2, 345353.
  • Leffler, C.T., Philippi, A.F., Leffler, S.G., Mosure, J.C. and Kim, P.D. (1999) Glucosamine, chondroitin and manganese ascorbate for degenerative joint disease of the knee or low back: a randomised, double-blind, placebo-controlled pilot study. Mil. Med. 164, 8591.
  • Lippiello, L., Woodward, J., Karpman, R. and Hammad, T.A. (2000) In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulphate. Clin. Orthop. 381, 229240.
  • May, S.A., Lees, P., Hooke, R.E., Peremans, K.Y. and Verschooten, F. (1994) Prostaglandin E2 in equine joint disease. Vlaams Diergeneesk. Tijdschr. 63, 187191.
  • McAlindon, T.E., LaValley, M.P., Gulin, J.P. and Felson, D.T. (2000) Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis [see comments]. J. Am. med. Ass. 283, 14691475.
  • McLaughlin, R. (2000) Management of chronic osteoarthritic pain. Vet. Clin. N. Am.: Small Anim. Pract. 30, 933949.
  • Mello, D.M., (Ed.) (2001) The comparative effects of hexosamines in the inhibition of articular cartilage degradation. In: Animal Science, East Lansing, Michigan State University, Michigan. p 101.
  • Mengshol, J.A., Vincenti, M.P., Coon, C.I., Barchowsky, A. and Brinckerhoff, C.E. (2000) Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthr. Rheum. 43, 801811.
  • Morreale, P., Manopulo, R., Galati, M., Boccanera, L., Saponati, G. and Bocchi, L. (1996) Comparison of the antiinflammatory efficacy of chondroitin sulphate and diclofenac sodium in patients with knee osteoarthritis. J. Rheumatol. 23, 13851391.
  • Morris, E.A. and Treadwell, B.V. (1994) Effect of interleukin 1 on articular cartilage from young and aged horses and comparison with metabolism of osteoarthritic cartilage. Am. J. vet. Res. 55, 138146.
  • Nerucci, F., Fioravanti, A., Cicero, M.R., Collodel, G. and Marcolongo, R. (2000) Effects of chondroitin sulphate and interleukin-1beta on human chondrocyte cultures exposed to pressurisation: a biochemical and morphological study. Osteoarthritis Cart. 8, 279287.
  • Pelletier, J.P., Jovanovic, D., Fernandes, J.C., Manning, P., Connor, J.R., Currie, M.G., Di Battista, J.A. and Martel Pelletier, J. (1998) Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthr. Rheum. 41, 12751286.
  • Pelletier, J.P., Jovanovic, D.V., Lascau-Coman, V., Fernandes, J.C., Manning, P.T., Connor, J.R., Currie, M.G. and Martel-Pelletier, J. (2000) Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: possible link with the reduction in chondrocyte apoptosis and caspase 3 level. Arthr. Rheum. 43, 12901299.
  • Pool, R.R. and Meagher, D.M. (1990) Pathologic findings and pathogenesis of racetrack injuries. Vet. Clin. N. Am.: Equine Pract. 6, 130.
  • Ratcliffe, A., Beauvais, P.J. and Saed Nejad, F. (1994) Differential levels of synovial fluid aggrecan aggregate components in experimental osteoarthritis and joint disuse. J. Orthop. Res. 12, 464473.
  • Reginster, J. Y., Deroisy, R., Rovati, L.C., Lee, R.L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J.E. and Gossett, C. (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357, 251256.
  • Ronca, F., Palmieri, L., Panicucci, P. and Ronca, G. (1998) Anti-inflammatory activity of chondroitin sulphate. Osteoarthritis Cart., Suppl. A. 6, 1421.
  • Rosselot, G., Reginato, A.M. and Leach, R.M. (1992) Development of a serum-free system to study the effect of growth hormone and insulinlike growth factor-I on cultured postembryonic growth plate chondrocytes. In Vitro cell Dev. Biol. 28A, 235244.
  • Sahap Atik, O. (1990) Leukotriene B4 and prostaglandin E2-like activity in synovial fluid in osteoarthritis. Prostaglandins Leukot. Essent. Fatty Acids 39, 253254.
  • Sandy, J.D., Gamett, D., Thompson, V. and Verscharen, C. (1998) Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can inhibited by glucosamine. Biochem. J. 335, 5966.
  • Sasaki, K., Hattori, T., Fujisawa, T., Takahashi, K., Inoue, H. and Takigawa, M. (1998) Nitric oxide mediates interleukin-1-induced gene expression of matrix metalloproteinases and basic fibroblast growth factor in cultured rabbit articular chondrocytes. J. Biochem. 123, 431439.
  • Thompson, C.C., Clegg, P.D. and Carter, S.D. (2001) Differential regulation of gelatinases by transforming growth factor beta-1 in normal equine chondrocytes. Osteoarthritis Cart. 9, 325331.
  • Thonar, E.J., Lenz, M.E., Klintworth, G.K., Caterson, B., Pachman, L.M., Glickman, P., Katz, R., Huff, J. and Kuettner, K.E. (1985) Quantification of keratan sulfate in blood as a marker of cartilage catabolism. Arthritis Rheum. 28, 13671376.
  • von Rechenberg, B., McIlwraith, C.W., Akens, M.K., Frisbie, D.D., Leutenegger, C. and Auer, J.A. (2000) Spontaneous production of nitric oxide (NO), prostaglandin (PGE2) and neutral metalloproteinases (NMPs) in media of explant cultures of equine synovial membrane and articular cartilage from normal and osteoarthritic joints. Equine vet. J. 32, 140150.